Hvsen Biotechnology Co., Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. Its products include tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. The company produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives. Hvsen Biotechnology Co., Ltd. was founded in 2002 and is based in Wuhan, China.
Metrics to compare | 300871 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300871PeersSector | |
---|---|---|---|---|
P/E Ratio | 109.9x | 33.0x | −0.5x | |
PEG Ratio | 0.29 | −1.03 | 0.00 | |
Price/Book | 2.8x | 3.1x | 2.6x | |
Price / LTM Sales | 3.2x | 4.6x | 3.2x | |
Upside (Analyst Target) | - | 10.3% | 42.0% | |
Fair Value Upside | Unlock | 1.4% | 6.6% | Unlock |